Ligand Pharma (LGND) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ligand Pharma (LGND) PT Raised to $237 at H.C. Wainwright
February 7, 2020 8:29 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Ligand Pharma (NASDAQ: LGND) to $237.00 (from $214.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, Ligand announced 4Q19 and 2019 financial results, posting GAAP EPS of ($0.43) and $33.13 per share, respectively, compared with our... More
